Novartis Results to Show Effects of Patent Expiration, Acquisitions

Dow Jones

07/15

0700 GMT - Novartis is expected to report lower core earnings for the second quarter due to the effect of patent expirations for key drugs and increased research-and-development spending from recent acquisitions, Citi analysts say in a research note. The Swiss drugmaker is expected to post a 12% drop in core earnings per share at constant currency to $2.15, according to Citi's estimate. This reflects a sales hit from generic competition for its Entresto, Promacta and Tasigna drugs, as well as the consolidation of research spending from recent acquisitions such as Avidity, the analysts say. It seems too early for a guidance upgrade, they add. Beyond the results, the analysts say they will be looking at Novartis's confidence on upcoming trial results for drug candidates pelacarsen, remibrutinib and del-desiran. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 15, 2026 03:00 ET (07:00 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2651437239"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651437239\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651437239?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651437239","market":"nz","top_or_hot":-1,"title":"Novartis Results to Show Effects of Patent Expiration, Acquisitions","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0700 GMT - Novartis is expected to report lower core earnings for the second quarter due to the effect of patent expirations for key drugs and increased research-and-development spending from recent acquisitions, Citi analysts say in a research note. The Swiss drugmaker is expected to post a 12% drop in core earnings per share at constant currency to $2.15, according to Citi's estimate. This reflects a sales hit from generic competition for its Entresto, Promacta and Tasigna drugs, as well as the consolidation of research spending from recent acquisitions such as Avidity, the analysts say. It seems too early for a guidance upgrade, they add. Beyond the results, the analysts say they will be looking at Novartis's confidence on upcoming trial results for drug candidates pelacarsen, remibrutinib and del-desiran. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 15, 2026 03:00 ET (07:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Results to Show Effects of Patent Expiration, Acquisitions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Results to Show Effects of Patent Expiration, Acquisitions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-15 15:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0700 GMT - Novartis is expected to report lower core earnings for the second quarter due to the effect of patent expirations for key drugs and increased research-and-development spending from recent acquisitions, Citi analysts say in a research note. The Swiss drugmaker is expected to post a 12% drop in core earnings per share at constant currency to $2.15, according to Citi's estimate. This reflects a sales hit from generic competition for its Entresto, Promacta and Tasigna drugs, as well as the consolidation of research spending from recent acquisitions such as Avidity, the analysts say. It seems too early for a guidance upgrade, they add. Beyond the results, the analysts say they will be looking at Novartis's confidence on upcoming trial results for drug candidates pelacarsen, remibrutinib and del-desiran. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 15, 2026 03:00 ET (07:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651437239","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651437239","pubTimestamp":1784098800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0700 GMT - Novartis is expected to report lower core earnings for the second quarter due to the effect of patent expirations for key drugs and increased research-and-development spending from recent acquisitions, Citi analysts say in a research note. The Swiss drugmaker is expected to post a 12% drop in core earnings per share at constant currency to $2.15, according to Citi's estimate. This reflects a sales hit from generic competition for its Entresto, Promacta and Tasigna drugs, as well as the consolidation of research spending from recent acquisitions such as Avidity, the analysts say. It seems too early for a guidance upgrade, they add. Beyond the results, the analysts say they will be looking at Novartis's confidence on upcoming trial results for drug candidates pelacarsen, remibrutinib and del-desiran.  Dow Jones NewswiresJuly 15, 2026 03:00 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","NVS":"诺华","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4578":"CAR-T","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","MEDX":"HORIZON KINETICS MEDICAL ETF","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","PPH":"VanEck Pharmaceutical ETF","BK4588":"碎股","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4007":"制药"},"translate_title":"诺华业绩显示专利到期、收购的影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PPH":0.6,"NVS":0.9,"MEDX":0.6},"content_text":"0700 GMT - Novartis is expected to report lower core earnings for the second quarter due to the effect of patent expirations for key drugs and increased research-and-development spending from recent acquisitions, Citi analysts say in a research note. The Swiss drugmaker is expected to post a 12% drop in core earnings per share at constant currency to $2.15, according to Citi's estimate. This reflects a sales hit from generic competition for its Entresto, Promacta and Tasigna drugs, as well as the consolidation of research spending from recent acquisitions such as Avidity, the analysts say. It seems too early for a guidance upgrade, they add. Beyond the results, the analysts say they will be looking at Novartis's confidence on upcoming trial results for drug candidates pelacarsen, remibrutinib and del-desiran. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 15, 2026 03:00 ET (07:00 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}